Kisho

Cascade Pharmaceuticals, Inc — Rare Disease Pipeline | Kisho | Kisho

Cascade Pharmaceuticals, Inc

Other

Orphan Designations

FDA Approvals

Rare Diseases

News Articles

Disease	Drug(s)	Designation	Approved
post 5-alpha-reductase inhibitors treatment syndrome	selective nonsteroidal FXR agonist	Orphan Designation	-
post-treatment Lyme disease syndrome	selective nonsteroidal FXR agonist	Orphan Designation	-
primary sclerosing cholangitis	3-(4-((3-endo)-3-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4- yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-2-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one	Orphan Designation	-
treatment-refractory schizophrenia	selective nonsteroidal FXR agonist	Orphan Designation	-